• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促性腺激素释放激素拮抗剂Nal-Glu与庚酸睾酮联合使用对正常男性促性腺激素水平的剂量效应

Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men.

作者信息

Bagatell C J, Rivier J E, Bremner W J

机构信息

University of Washington School of Medicine, Seattle, USA.

出版信息

Fertil Steril. 1995 Jul;64(1):139-45.

PMID:7789550
Abstract

OBJECTIVE

To test the hypothesis that over a 4-week treatment period, Nal-Glu GnRH antagonist ([AcD2Nal1, D4ClPhe2, D3Pal3, Arg5, DGlu6 [AA], DAla10] GnRH) at a dose of 200 micrograms/kg per day SC would suppress levels of immunologically active and biologically active LH and FSH more completely than a dose of 100 micrograms/kg per day.

DESIGN

Placebo controlled clinical study.

SETTING

A university community.

SUBJECTS

Thirty normal male volunteers.

INTERVENTIONS

We administered Nal-Glu at doses of 0, 100, and 200 micrograms/kg body weight per day in combination with T enanthate, 50 mg IM weekly, to separate groups of men (9 or 10 men per group) for 4 weeks.

RESULTS

Serum levels of immunologically active and biologically active gonadotropins were suppressed similarly in both groups of men who received Nal-Glu; this suppression was significantly greater than in the men who received placebo + T. Local side effects were more severe in the Nal-Glu 200 micrograms/kg per day group.

CONCLUSIONS

Administration of Nal-Glu in combination with T suppresses gonadotropins more completely than does T alone, but at doses > 100 micrograms/kg, gonadotropins are not suppressed additionally with larger doses of Nal-Glu. Subjects experienced greater local discomfort and side effects with the higher dosage. These findings suggest that dosages of Nal-Glu of > 100 micrograms/kg per day may have no advantage over the 100-micrograms/kg dose in a male contraceptive regimen.

摘要

目的

验证以下假设,即在为期4周的治疗期内,每天皮下注射剂量为200微克/千克的那格列奈 - 谷氨酸促性腺激素释放激素拮抗剂([AcD2Nal1, D4ClPhe2, D3Pal3, Arg5, DGlu6 [AA], DAla10] GnRH)比每天100微克/千克的剂量能更完全地抑制免疫活性和生物活性促黄体生成素(LH)及促卵泡生成素(FSH)的水平。

设计

安慰剂对照临床研究。

地点

大学社区。

受试者

30名正常男性志愿者。

干预措施

我们将每天剂量为0、100和200微克/千克体重的那格列奈 - 谷氨酸与庚酸睾酮(每周肌肉注射50毫克)联合,分别给予不同组的男性(每组9或10名男性),为期4周。

结果

接受那格列奈 - 谷氨酸的两组男性中,免疫活性和生物活性促性腺激素的血清水平受到的抑制相似;这种抑制明显大于接受安慰剂 + 庚酸睾酮的男性。每天200微克/千克那格列奈 - 谷氨酸组的局部副作用更严重。

结论

那格列奈 - 谷氨酸与庚酸睾酮联合使用比单独使用庚酸睾酮能更完全地抑制促性腺激素,但剂量大于100微克/千克时,更高剂量的那格列奈 - 谷氨酸不会额外抑制促性腺激素。受试者在较高剂量时出现了更严重的局部不适和副作用。这些发现表明,在男性避孕方案中,每天剂量大于100微克/千克的那格列奈 - 谷氨酸可能并不比100微克/千克的剂量更具优势。

相似文献

1
Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men.促性腺激素释放激素拮抗剂Nal-Glu与庚酸睾酮联合使用对正常男性促性腺激素水平的剂量效应
Fertil Steril. 1995 Jul;64(1):139-45.
2
A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.睾酮与一种新型强效促性腺激素释放激素拮抗剂对正常男性促性腺激素和抑制素水平抑制作用的比较。
J Clin Endocrinol Metab. 1989 Jul;69(1):43-8. doi: 10.1210/jcem-69-1-43.
3
Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.联合使用那法瑞林-谷氨酸促性腺激素释放激素拮抗剂和庚酸睾酮诱导正常男性无精子症
J Clin Endocrinol Metab. 1992 Aug;75(2):476-83. doi: 10.1210/jcem.75.2.1639948.
4
Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.促性腺激素释放激素拮抗剂联合睾酮(T)与单独使用T作为潜在男性避孕方案的比较。
J Clin Endocrinol Metab. 1993 Aug;77(2):427-32. doi: 10.1210/jcem.77.2.8345047.
5
Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.正常男性注射促黄体生成素释放激素拮抗剂后促黄体生成素(LH)、睾酮和α亚基脉冲的持续一致性
J Clin Endocrinol Metab. 1990 May;70(5):1472-8. doi: 10.1210/jcem-70-5-1472.
6
Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men.正常老年男性对一种强效促性腺激素释放激素拮抗剂的激素反应。
J Clin Endocrinol Metab. 1990 Oct;71(4):881-8. doi: 10.1210/jcem-71-4-881.
7
Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.在排卵期前后给予促性腺激素释放激素(GnRH)拮抗剂(Nal-Glu)的影响:促黄体生成素高峰需要GnRH的分泌。
J Clin Endocrinol Metab. 1994 Feb;78(2):343-7. doi: 10.1210/jcem.78.2.8106622.
8
Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.对健康男性单次注射促性腺激素释放激素拮抗剂Nal-Lys(抗生育肽)。
Fertil Steril. 1993 Oct;60(4):680-5. doi: 10.1016/s0015-0282(16)56222-0.
9
Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.正常男性急性或长期给予促黄体生成素释放激素拮抗剂后垂体和性腺功能的抑制模式
J Clin Endocrinol Metab. 1989 Feb;68(2):446-54. doi: 10.1210/jcem-68-2-446.
10
Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men.
Fertil Steril. 1991 Jan;55(1):156-64.

引用本文的文献

1
Continuing the search for a hormonal male contraceptive.继续寻找荷尔蒙男性避孕药。
Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:83-94. doi: 10.1016/j.bpobgyn.2020.02.003. Epub 2020 Feb 19.
2
The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats.地加瑞克化学去势对骨转换的影响:雄性大鼠的骨密度和生物力学骨特性
Int J Endocrinol Metab. 2018 Jul 2;16(3):e64038. doi: 10.5812/ijem.64038. eCollection 2018 Jul.
3
Evaluation of degarelix in the management of prostate cancer.
评价地加瑞克在前列腺癌治疗中的应用。
Cancer Manag Res. 2010 Jan 25;2:39-52. doi: 10.2147/cmar.s8841.
4
Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.地加瑞克,一种新型 GnRH 拮抗剂,与考替瑞林、阿巴瑞克和加尼瑞克相比,在人体皮肤样本的离体模型中引起的组胺释放最小。
Br J Clin Pharmacol. 2010 Oct;70(4):580-7. doi: 10.1111/j.1365-2125.2010.03730.x.